- In September 2024, Boston Scientific Corporation received FDA approval to expand the indications for its INGEVITY+ Pacing Leads, now authorized for use in conduction system pacing (CSP) and for sensing the left bundle branch area (LBBA). This innovative technique offers a promising alternative to traditional right ventricular pacing for patients with symptomatic bradycardia. This approval underscores Boston Scientific’s commitment to advancing cardiac care and represents a significant development within the global cardiac pacemaker market
- In June 2024, Abbott received CE Mark approval for its AVEIR Dual Chamber (DR) Leadless Pacemaker, marking a significant milestone as the first leadless pacemaker system designed for dual-chamber treatment of abnormal heart rhythms. This innovative system comprises two small devices—AVEIR VR for the right ventricle and AVEIR AR for the right atrium—that communicate wirelessly to deliver coordinated therapy. The approval of the AVEIR system not only addresses the growing demand for minimally invasive solutions but also aligns with the market's shift towards leadless pacemakers, which offer reduced complications and faster recovery times
- In March 2024, MicroPort CRM launched the ALIZEA Bluetooth pacemaker system in the U.S., marking a significant advancement in cardiac care. The first implantation of the system was successfully performed at PIH Health Downey Hospital. The ALIZEA system features a cutting-edge pacemaker paired with VEGA pacing leads, enabling real-time monitoring and management of heart rhythms. This development contributes to the global cardiac pacemakers market by addressing the increasing demand for remote patient management solutions and enhancing the overall patient experience
- In June 2021, Medtronic launched the Micra AV, a compact and self-contained pacemaker engineered to deliver advanced pacing technology for patients with atrioventricular (AV) block. This device features a minimally invasive implantation procedure, highlighting Medtronic's innovative approach to enhancing cardiac care. It addresses the growing demand for less invasive, efficient solutions in the management of heart rhythm disorders
- In January 2021, Boston Scientific Corporation announced its intention to acquire Preventice Solutions, a leading developer specializing in remote cardiac monitoring technologies. This acquisition contributes to the global cardiac pacemakers market, as it underscores the growing trend towards integrated cardiac care solutions that combine device technology with remote monitoring capabilities
